Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Cardiorenal Syndrome Type 1: Activation of Dual Apoptotic Pathways.

Pastori S, Virzì GM, Brocca A, de Cal M, Cantaluppi V, Castellani C, Fedrigo M, Thiene G, Valente ML, Angelini A, Vescovo G, Ronco C.

Cardiorenal Med. 2015 Oct;5(4):306-15. doi: 10.1159/000438831. Epub 2015 Sep 2.

2.

Detection and evaluation of renal biomarkers in a swine model of acute myocardial infarction and reperfusion.

Duan SY, Xing CY, Zhang B, Chen Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8336-47. eCollection 2015.

3.

Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney.

Palazzuoli A, Ruocco G, Ronco C, McCullough PA.

Crit Care. 2015 Sep 3;19:296. doi: 10.1186/s13054-015-1017-3.

4.

Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.

Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y.

Biomed Res Int. 2014;2014:704289. doi: 10.1155/2014/704289. Epub 2014 Nov 10.

5.

Cardiorenal syndrome type 2: from diagnosis to optimal management.

De Vecchis R, Baldi C.

Ther Clin Risk Manag. 2014 Nov 12;10:949-61. doi: 10.2147/TCRM.S63255. eCollection 2014. Review.

6.
7.

Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.

Palazzuoli A, Pellegrini M, Ruocco G, Martini G, Franci B, Campagna MS, Gilleman M, Nuti R, McCullough PA, Ronco C.

Crit Care. 2014 Jun 28;18(3):R134. doi: 10.1186/cc13952.

8.

Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.

Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y; AVCMA investigators.

J Clin Pharmacol. 2013 Dec;53(12):1277-85. doi: 10.1002/jcph.197. Epub 2013 Oct 19.

9.

Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches.

Koniari K, Parissis J, Paraskevaidis I, Anastasiou-Nana M.

Eur Heart J Acute Cardiovasc Care. 2012 Sep;1(3):256-68. doi: 10.1177/2048872612457044.

10.

Cardiorenal syndrome: a cardiologist's perspective of pathophysiology.

Anand IS.

Clin J Am Soc Nephrol. 2013 Oct;8(10):1800-7. doi: 10.2215/CJN.04090413. Epub 2013 Jul 25. Review.

11.

Noncardiac comorbidities and acute heart failure patients.

Mentz RJ, Felker GM.

Heart Fail Clin. 2013 Jul;9(3):359-67, vii. doi: 10.1016/j.hfc.2013.04.003. Epub 2013 May 23. Review.

12.

Approaches to decongestion in patients with acute decompensated heart failure.

Muñoz D, Felker GM.

Curr Cardiol Rep. 2013 Feb;15(2):335. doi: 10.1007/s11886-012-0335-1. Review.

13.

Ultrafiltration in decompensated heart failure with cardiorenal syndrome.

Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network.

N Engl J Med. 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357. Epub 2012 Nov 6.

14.

Worsening renal function is not associated with response to treatment in acute heart failure.

Ather S, Bavishi C, McCauley MD, Dhaliwal A, Deswal A, Johnson S, Chan W, Aguilar D, Pritchett AM, Ramasubbu K, Wehrens XH, Bozkurt B.

Int J Cardiol. 2013 Sep 1;167(5):1912-7. doi: 10.1016/j.ijcard.2012.05.004. Epub 2012 May 25.

15.

Cardiorenal syndrome: Resistant to diuretics, sensitive to ultraflitration.

Aundhakar SC, Mahajan SK, Mane MB, Lakhotia AN, Mahajani VV.

J Cardiovasc Dis Res. 2012 Apr;3(2):173-5. doi: 10.4103/0975-3583.95379.

16.

Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network.

Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O'Connor CM, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E.

J Card Fail. 2012 Mar;18(3):176-82. doi: 10.1016/j.cardfail.2011.12.009. Epub 2012 Feb 2.

17.

Predictors of re-hospitalization in patients with chronic heart failure.

Zaya M, Phan A, Schwarz ER.

World J Cardiol. 2012 Feb 26;4(2):23-30. doi: 10.4330/wjc.v4.i2.23.

18.

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?

Athyros VG, Katsiki N, Tziomalos K, Karagiannis A.

Open Cardiovasc Med J. 2011;5:226-30. doi: 10.2174/1874192401105010226. Epub 2011 Dec 2. No abstract available.

19.

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ.

Eur J Heart Fail. 2011 Aug;13(8):846-51. doi: 10.1093/eurjhf/hfr087.

20.

Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization.

Testani JM, Cappola TP, McCauley BD, Chen J, Shen J, Shannon RP, Kimmel SE.

Am Heart J. 2011 May;161(5):944-9. doi: 10.1016/j.ahj.2011.02.005.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk